Literature DB >> 15142209

Antibiotic resistance profile of the subgingival microbiota following systemic or local tetracycline therapy.

Rosa Maria J Rodrigues1, Cristiane Gonçalves, Renata Souto, Eduardo Jorge Feres-Filho, Milton Uzeda, Ana Paula V Colombo.   

Abstract

BACKGROUND: Tetracyclines have been extensively used as adjunctives to conventional periodontal therapy. Emergence of resistant strains, however, has been reported. This study evaluated longitudinally the tetracycline resistance patterns of the subgingival microbiota of periodontitis subjects treated with systemic or local tetracycline therapy+scaling and root planing (SRP).
METHODS: Thirty chronic periodontitis patients were randomly assigned to three groups: SRP+500 mg of systemic tetracycline twice/day for 14 days; SRP alone and SRP+tetracycline fibers (Actsite) at four selected sites for 10 days. Subgingival plaque samples were obtained from four sites with probing pocket depths (PPD)> or =6 mm in each patient at baseline, 1 week, 3, 6 and 12 months post-therapy. Samples were dispersed and diluted in pre-reduced anaerobically sterilized Ringer's solution, plated on Trypticase Soy Agar (TSA)+5% blood with or without 4 microg/ml of tetracycline and incubated anaerobically for 10 days. The percentage of resistant microorganisms were determined and the isolates identified by DNA probes and the checkerboard method. Significance of differences among and within groups over time was sought using the Kruskal-Wallis and Friedman tests, respectively.
RESULTS: The percentage of resistant microorganisms increased significantly at 1 week in the tetracycline groups, but dropped to baseline levels over time. The SRP+Actsite group presented the lowest proportions of resistant species at 6 and 12 months. No significant changes were observed in the SRP group. The predominant tetracycline-resistant species included Streptococcus spp., Veillonela parvula, Peptostreptococcus micros, Prevotella intermedia, Gemella morbillorum and Actinobacillus actinomycetemcomitans (Aa). A high percentage of sites with resistant Aa, Porphyromonas gingivalis and Tanerella forsythensis was observed in all groups at baseline. However, T. forsythensis was not detected in any group and P. gingivalis was not present in the SRP+Actsite group at 1 year post-therapy. Aa was still frequently detected in all groups after therapy. However, the greatest reduction was observed in the SRP+Actsite group.
CONCLUSION: Local or systemically administered tetracycline results in transitory selection of subgingival species intrinsically resistant to this drug. Although the percentage of sites harboring periodontal pathogens resistant to tetracycline were quite elevated in this population, both therapies were effective in reducing their prevalence over time.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15142209     DOI: 10.1111/j.1600-051X.2004.00493.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  20 in total

1.  Local Drug Delivery with Tetracycline Fiber : An Alternative to Surgical Periodontal Therapy.

Authors:  M Panwar; S H Gupta
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 2.  Microbiota and nonalcoholic steatohepatitis.

Authors:  Kento Imajo; Masato Yoneda; Yuji Ogawa; Koichiro Wada; Atsushi Nakajima
Journal:  Semin Immunopathol       Date:  2013-12-14       Impact factor: 9.623

3.  Plumbagin suppresses chronic periodontitis in rats via down-regulation of TNF-α, IL-1β and IL-6 expression.

Authors:  Xin-Yi Zheng; Chuan-Yuan Mao; Han Qiao; Xi Zhang; Li Yu; Ting-Yu Wang; Er-Yi Lu
Journal:  Acta Pharmacol Sin       Date:  2017-05-29       Impact factor: 6.150

4.  Systemic antibiotics and tooth loss in periodontal disease.

Authors:  J Cunha-Cruz; P P Hujoel; G Maupome; B Saver
Journal:  J Dent Res       Date:  2008-09       Impact factor: 6.116

5.  Biodegradable nanofibrous drug delivery systems: effects of metronidazole and ciprofloxacin on periodontopathogens and commensal oral bacteria.

Authors:  Marco C Bottino; Rodrigo A Arthur; R Aaron Waeiss; Krzysztof Kamocki; Karen S Gregson; Richard L Gregory
Journal:  Clin Oral Investig       Date:  2014-02-18       Impact factor: 3.573

6.  Multiple applications of flurbiprofen and chlorhexidine chips in patients with chronic periodontitis: a randomized, double blind, parallel, 2-arms clinical trial.

Authors:  Eli E Machtei; Ilan Hirsh; Maher Falah; Eyal Shoshani; Avi Avramoff; Adel Penhasi
Journal:  J Clin Periodontol       Date:  2011-09-15       Impact factor: 8.728

7.  Multilevel analysis of clinical parameters in chronic periodontitis after root planing/scaling, surgery, and systemic and local antibiotics: 2-year results.

Authors:  Ibrahimu Mdala; Anne D Haffajee; Sigmund S Socransky; Birgitte Freiesleben de Blasio; Magne Thoresen; Ingar Olsen; J Max Goodson
Journal:  J Oral Microbiol       Date:  2012-04-24       Impact factor: 5.474

8.  Deep sequencing of the oral microbiome reveals signatures of periodontal disease.

Authors:  Bo Liu; Lina L Faller; Niels Klitgord; Varun Mazumdar; Mohammad Ghodsi; Daniel D Sommer; Theodore R Gibbons; Todd J Treangen; Yi-Chien Chang; Shan Li; O Colin Stine; Hatice Hasturk; Simon Kasif; Daniel Segrè; Mihai Pop; Salomon Amar
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

Review 9.  Effects of timing of adjunctive systemic antibiotics on the clinical outcome of periodontal therapy: A systematic review.

Authors:  Lamiaa Abdallaoui-Maan; Amal Bouziane
Journal:  J Clin Exp Dent       Date:  2020-03-01

10.  Antibiotic susceptibility of Aggregatibacter actinomycetemcomitans JP2 in a biofilm.

Authors:  Orit Oettinger-Barak; Stuart G Dashper; Deanne V Catmull; Geoffrey G Adams; Michael N Sela; Eli E Machtei; Eric C Reynolds
Journal:  J Oral Microbiol       Date:  2013-05-08       Impact factor: 5.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.